Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
| ▸ | PRKCA | P17252 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ANTXR2 | P58335 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | HMGCR | P04035 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20023215 | 1.00 | TSHR (0.47) | TSHRPAX8PRKCAAKT1PTK2 | |
| SCHEMBL21576977 | 0.96 | TSHR (0.44) | TSHRPAX8PRKCAAKT1PTK2 | |
| SCHEMBL22039261 | 0.96 | TSHR (0.44) | TSHRPAX8PRKCAAKT1PTK2 | |
| SCHEMBL21665520 | 0.96 | TSHR (0.44) | TSHRPAX8PRKCAAKT1PTK2 | |
| SCHEMBL18031017 | 0.95 | TSHR (0.44) | TSHRPAX8PRKCAAKT1PTK2 | |
| SCHEMBL23011621 | 0.94 | PTPN1 (0.43) | TSHRPAX8PRKCAAKT1PTK2 | |
| SCHEMBL22063762 | 0.93 | TSHR (0.41) | TSHRPAX8PRKCAAKT1PTK2 | |
| SCHEMBL17552001 | 0.92 | TSHR (0.48) | TSHRPAX8PRKCAAKT1PTK2 | |
| SCHEMBL14199417 | 0.91 | TSHR (0.47) | TSHRPAX8PRKCAAKT1PTK2 | |
| SCHEMBL18654280 | 0.91 | PTPN1 (0.52) | TSHRPTPN1USP2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018515-A1 | COMPLEMENT FACTOR B (CFB) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-01-18 | — | — | US | disclosed |
| US-11198876-B2 | Compositions and methods for inhibiting expression of TMPRSS6 gene | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-11091759-B2 | Methods and compositions for treating a Serpinc1-associated disorder | GENZYME CORPORATION (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210228614-A1 | LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | THE UAB RESEARCH FOUNDATION | 2021-07-29 | — | — | US | disclosed |
| US-11053495-B2 | Multi-targeted single entity conjugates | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| EP-3218487-B1 | HEPATITIS D VIRUS (HDV) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS INC (US) | 2021-06-16 | — | — | EP | disclosed |
| US-20200339998-A1 | COMPLEMENT COMPONENT iRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. | 2020-10-29 | — | — | US | disclosed |
| US-10570393-B2 | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10400238-B2 | Polynucleotide agents targeting complement component C5 and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180208927-A1 | MULTI-TARGETED SINGLE ENTITY CONJUGATES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-07-26 | — | — | US | disclosed |
| WO-2015179724-A1 | ANGIOTENSINOGEN (AGT) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
| WO-2015089368-A2 | COMPLEMENT COMPONENT IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015051318-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015050990-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-04-09 | — | — | WO | disclosed |
| WO-2012177947-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF APOLIPOPROTEIN C-III (APOC3) GENES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012135246-A2 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TMPRSS6 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2011153323-A9 | COMPOSITIONS AND METHODS DIRECTED TO TREATING LIVER FIBROSIS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2011153323-A2 | COMPOSITIONS AND METHODS DIRECTED TO TREATING LIVER FIBROSIS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-12-08 | — | — | WO | disclosed |
| WO-2011091396-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MYLIP/IDOL GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2009073809-A2 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091759-B2 | Methods and compositions for treating a Serpinc1-associated disorder | SERPINC1, SERPINH1, SERPINE1 | TSHR 4337/4885PAX8 2922/4885PRKCA 2934/4885 |
| US-20200339998-A1 | COMPLEMENT COMPONENT iRNA COMPOSITIONS AND METHODS OF USE THEREOF | CFB, CFH, HNRNPA2B1 | TSHR 3513/4885PAX8 1791/4885PRKCA 3142/4885 |
| US-10400238-B2 | Polynucleotide agents targeting complement component C5 and methods of use thereof | C5, C3AR1, NT5C3B | TSHR 3552/4885PAX8 3519/4885PRKCA 3899/4885 |
| US-11198876-B2 | Compositions and methods for inhibiting expression of TMPRSS6 gene | TMPRSS6, TMPRSS2, TMPRSS11D | TSHR 3775/4885PAX8 2815/4885PRKCA 1811/4885 |
| US-20210228614-A1 | LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | LDHA, LDHB, HAO1 | TSHR 4604/4885PAX8 1103/4885PRKCA 1202/4885 |
| US-10570393-B2 | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof | TEK, RNASE1, LDLR | TSHR 2165/4885PAX8 2273/4885PRKCA 822/4885 |
| US-11053495-B2 | Multi-targeted single entity conjugates | SNRPE, DDX21, RNMT | TSHR 1731/4885PAX8 2498/4885PRKCA 4293/4885 |
| US-20240018515-A1 | COMPLEMENT FACTOR B (CFB) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | CFB, CFH, RNASE1 | TSHR 2605/4885PAX8 2719/4885PRKCA 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.